The first patient has been dosed to begin the phase 3 CLARIFY trial, testing the diagnostic performance of the Cu-SAR-bisPSMAfor patients with prostate ...

I have an immune disorder called selective IGA deficiency or SigAD. What it means is that the protein in the blood immunoglobulin is lacking a defense ...

A recent study found that breast cancer-specific survival outcomes were worse for patients with invasive lobular carcinoma when compared with patients with ...

The Food and Drug Administration (FDA) placed a clinical hold on the clinical trial evaluating the novel drug, LN-145 TIL, for patients with non-small cell ...

There’s a community inside you. It’s made up of trillions of microbes, including bacteria, fungi and even viruses.   This is called the microbiome.   ...

The year 2023 has come and gone, and we figured that now is the perfect time to look back on some of the top cancer-related stories from the year.Topics ...

A phase 2a trial of novel monotherapy GB2064 demonstrated a reduction of fibrosis in the bone marrow, which helps slow down cancer progression, in patients ...

Yesterday, I took my son for a haircut and found myself in a salon full of floor-to-ceiling mirrors. There, I couldn’t get away from my reflection where I ...

CURE looked back at the most read and influential stories on CLL throughout 2023.In 2023, the chronic lymphocytic leukemia (CLL) space was full of ...

Johnson & Johnson is seeking approval from the Food and Drug Administration (FDA) for Rybrevant (amivantamab-vmjw) with lazertinib via two separate ...